All In Biotech

Drug Trial Radar · NCT02530905

Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients

A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration, Safety, Tolerability, and Pharmacokinetics Study Followed by an Open-Label Safety and Efficacy Evaluation of SRP-4045 in Advanced-Stage Patients With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Last checked: Nov 20, 2026Latest source record: May 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

12

Actual

Start

Oct 8, 2015

Primary completion

Oct 3, 2018

Study completion Oct 3, 2018

Sponsor

Lead sponsor
Sarepta Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 21, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 7 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human dose-titration and open-label extension study to assess safety, tolerability, and pharmacokinetics of SRP-4045 in advanced-stage Duchenne muscular dystrophy (DMD) patients with deletions amenable to exon 45 skipping.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • SRP-4045Drug

    SRP-4045 solution for IV infusion.

  • PlaceboDrug

    SRP-4045 placebo-matching solution for IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Baseline up to Week 148
  2. Number of Participants With Potentially Clinically Significant (PCS) Laboratory Abnormalities Reported as TEAEsTime frame: Baseline up to Week 148
  3. Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEsTime frame: Baseline up to Week 148
  4. Number of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Reported as TEAEsTime frame: Baseline up to Week 148
  5. Number of Participants With Potentially Clinically Significant Abnormalities in Echocardiograms (ECHO)Time frame: Baseline up to Week 148

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • David Geffen School of Medicine at UCLA

    Los Angeles, California

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Kennedy Krieger Institute

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.